Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
15
VTAK Quote, Financials, Valuation and Earnings
Last price:
$1.48
Seasonality move
:
-23.89%
Day range:
$1.57 - $1.64
52-week range:
$1.14 - $15.68
Dividend yield:
0%
P/E ratio:
0.40x
P/S ratio:
7.43x
P/B ratio:
0.29x
Volume:
20.9K
Avg. volume:
123.1K
1-year change:
-76.24%
Market cap:
$1.9M
Revenue:
$420K
EPS (TTM):
-$34.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
ABT
Abbott Laboratories
|
$11.8B | $1.49 | 6.14% | 54.88% | $133.39 |
|
ARAY
Accuray, Inc.
|
$100.9M | -$0.11 | -1.19% | -296.83% | $2.53 |
|
ATEC
Alphatec Holdings, Inc.
|
$212.2M | $0.04 | 17.11% | -88.21% | $24.62 |
|
BSX
Boston Scientific Corp.
|
$5.3B | $0.78 | 11.3% | 75.74% | $104.75 |
|
PSTV
Plus Therapeutics, Inc.
|
$1.2M | -$0.04 | 22.78% | -97.49% | $5.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VTAK
Catheter Precision, Inc.
|
$1.58 | -- | $1.9M | 0.40x | $0.00 | 0% | 7.43x |
|
ABT
Abbott Laboratories
|
$114.12 | $133.39 | $198.3B | 30.70x | $0.63 | 2.1% | 4.50x |
|
ARAY
Accuray, Inc.
|
$0.55 | $2.53 | $65.5M | 149.00x | $0.00 | 0% | 0.14x |
|
ATEC
Alphatec Holdings, Inc.
|
$13.47 | $24.62 | $2B | -- | $0.00 | 0% | 2.64x |
|
BSX
Boston Scientific Corp.
|
$76.22 | $104.75 | $113.1B | 39.31x | $0.00 | 0% | 5.67x |
|
PSTV
Plus Therapeutics, Inc.
|
$0.30 | $5.50 | $41.2M | -- | $0.00 | 0% | 4.80x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VTAK
Catheter Precision, Inc.
|
68.63% | 0.175 | 537.37% | 0.41x |
|
ABT
Abbott Laboratories
|
21.33% | 0.218 | 6.98% | 1.05x |
|
ARAY
Accuray, Inc.
|
76.53% | 1.787 | 177.87% | 0.52x |
|
ATEC
Alphatec Holdings, Inc.
|
94.3% | 1.734 | 18.93% | 1.24x |
|
BSX
Boston Scientific Corp.
|
33.07% | 0.600 | 8.45% | 0.94x |
|
PSTV
Plus Therapeutics, Inc.
|
0.41% | -3.087 | 0.02% | 1.22x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
ABT
Abbott Laboratories
|
$6.1B | $2.4B | 10.13% | 12.91% | 20.68% | $2.6B |
|
ARAY
Accuray, Inc.
|
$24.1M | -$5.5M | -14.23% | -60.6% | -5.37% | -$21.6M |
|
ATEC
Alphatec Holdings, Inc.
|
$130.4M | -$5.4M | -23.65% | -1092.5% | -2.52% | $5.7M |
|
BSX
Boston Scientific Corp.
|
$3.6B | $1.2B | 8.3% | 12.55% | 22.93% | $1B |
|
PSTV
Plus Therapeutics, Inc.
|
$1.3M | -$4.5M | -- | -- | -320.83% | -$2.6M |
Catheter Precision, Inc. vs. Competitors
-
Which has Higher Returns VTAK or ABT?
Abbott Laboratories has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of 15.71%. Catheter Precision, Inc.'s return on equity of -192.05% beat Abbott Laboratories's return on equity of 12.91%.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M ABTAbbott Laboratories53.5% $1.03 $66.9B -
What do Analysts Say About VTAK or ABT?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 2305.14%. On the other hand Abbott Laboratories has an analysts' consensus of $133.39 which suggests that it could grow by 16.89%. Given that Catheter Precision, Inc. has higher upside potential than Abbott Laboratories, analysts believe Catheter Precision, Inc. is more attractive than Abbott Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 ABTAbbott Laboratories16 7 0 -
Is VTAK or ABT More Risky?
Catheter Precision, Inc. has a beta of -1.409, which suggesting that the stock is 240.927% less volatile than S&P 500. In comparison Abbott Laboratories has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.919%.
-
Which is a Better Dividend Stock VTAK or ABT?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Abbott Laboratories offers a yield of 2.1% to investors and pays a quarterly dividend of $0.63 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. Abbott Laboratories pays out 64.54% of its earnings as a dividend. Abbott Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios VTAK or ABT?
Catheter Precision, Inc. quarterly revenues are $226K, which are smaller than Abbott Laboratories quarterly revenues of $11.5B. Catheter Precision, Inc.'s net income of -$2.3M is lower than Abbott Laboratories's net income of $1.8B. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while Abbott Laboratories's PE ratio is 30.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 7.43x versus 4.50x for Abbott Laboratories. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.7.43x 0.40x $226K -$2.3M ABTAbbott Laboratories4.50x 30.70x $11.5B $1.8B
-
Which has Higher Returns VTAK or ARAY?
Accuray, Inc. has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of -13.47%. Catheter Precision, Inc.'s return on equity of -192.05% beat Accuray, Inc.'s return on equity of -60.6%.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M ARAYAccuray, Inc.23.54% -$0.11 $227.6M -
What do Analysts Say About VTAK or ARAY?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 2305.14%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 357.84%. Given that Catheter Precision, Inc. has higher upside potential than Accuray, Inc., analysts believe Catheter Precision, Inc. is more attractive than Accuray, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 ARAYAccuray, Inc.2 0 0 -
Is VTAK or ARAY More Risky?
Catheter Precision, Inc. has a beta of -1.409, which suggesting that the stock is 240.927% less volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.192, suggesting its more volatile than the S&P 500 by 19.162%.
-
Which is a Better Dividend Stock VTAK or ARAY?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or ARAY?
Catheter Precision, Inc. quarterly revenues are $226K, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. Catheter Precision, Inc.'s net income of -$2.3M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 7.43x versus 0.14x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.7.43x 0.40x $226K -$2.3M ARAYAccuray, Inc.0.14x 149.00x $102.2M -$13.8M
-
Which has Higher Returns VTAK or ATEC?
Alphatec Holdings, Inc. has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of -10.21%. Catheter Precision, Inc.'s return on equity of -192.05% beat Alphatec Holdings, Inc.'s return on equity of -1092.5%.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M ATECAlphatec Holdings, Inc.61.24% -$0.14 $632.1M -
What do Analysts Say About VTAK or ATEC?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 2305.14%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 82.74%. Given that Catheter Precision, Inc. has higher upside potential than Alphatec Holdings, Inc., analysts believe Catheter Precision, Inc. is more attractive than Alphatec Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 ATECAlphatec Holdings, Inc.8 1 0 -
Is VTAK or ATEC More Risky?
Catheter Precision, Inc. has a beta of -1.409, which suggesting that the stock is 240.927% less volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.020, suggesting its more volatile than the S&P 500 by 1.994%.
-
Which is a Better Dividend Stock VTAK or ATEC?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or ATEC?
Catheter Precision, Inc. quarterly revenues are $226K, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $212.9M. Catheter Precision, Inc.'s net income of -$2.3M is higher than Alphatec Holdings, Inc.'s net income of -$21.7M. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 7.43x versus 2.64x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.7.43x 0.40x $226K -$2.3M ATECAlphatec Holdings, Inc.2.64x -- $212.9M -$21.7M
-
Which has Higher Returns VTAK or BSX?
Boston Scientific Corp. has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of 12.68%. Catheter Precision, Inc.'s return on equity of -192.05% beat Boston Scientific Corp.'s return on equity of 12.55%.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M BSXBoston Scientific Corp.68.5% $0.45 $36.4B -
What do Analysts Say About VTAK or BSX?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 2305.14%. On the other hand Boston Scientific Corp. has an analysts' consensus of $104.75 which suggests that it could grow by 37.43%. Given that Catheter Precision, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Catheter Precision, Inc. is more attractive than Boston Scientific Corp..
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 BSXBoston Scientific Corp.25 0 0 -
Is VTAK or BSX More Risky?
Catheter Precision, Inc. has a beta of -1.409, which suggesting that the stock is 240.927% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.688, suggesting its less volatile than the S&P 500 by 31.155%.
-
Which is a Better Dividend Stock VTAK or BSX?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or BSX?
Catheter Precision, Inc. quarterly revenues are $226K, which are smaller than Boston Scientific Corp. quarterly revenues of $5.3B. Catheter Precision, Inc.'s net income of -$2.3M is lower than Boston Scientific Corp.'s net income of $670M. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while Boston Scientific Corp.'s PE ratio is 39.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 7.43x versus 5.67x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.7.43x 0.40x $226K -$2.3M BSXBoston Scientific Corp.5.67x 39.31x $5.3B $670M
-
Which has Higher Returns VTAK or PSTV?
Plus Therapeutics, Inc. has a net margin of -1037.17% compared to Catheter Precision, Inc.'s net margin of -316.61%. Catheter Precision, Inc.'s return on equity of -192.05% beat Plus Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M PSTVPlus Therapeutics, Inc.93.84% -$0.04 $5.1M -
What do Analysts Say About VTAK or PSTV?
Catheter Precision, Inc. has a consensus price target of --, signalling upside risk potential of 2305.14%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1735.78%. Given that Catheter Precision, Inc. has higher upside potential than Plus Therapeutics, Inc., analysts believe Catheter Precision, Inc. is more attractive than Plus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTAKCatheter Precision, Inc.0 0 0 PSTVPlus Therapeutics, Inc.4 0 0 -
Is VTAK or PSTV More Risky?
Catheter Precision, Inc. has a beta of -1.409, which suggesting that the stock is 240.927% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.173%.
-
Which is a Better Dividend Stock VTAK or PSTV?
Catheter Precision, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Catheter Precision, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTAK or PSTV?
Catheter Precision, Inc. quarterly revenues are $226K, which are smaller than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Catheter Precision, Inc.'s net income of -$2.3M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Catheter Precision, Inc.'s price-to-earnings ratio is 0.40x while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Catheter Precision, Inc. is 7.43x versus 4.80x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTAKCatheter Precision, Inc.7.43x 0.40x $226K -$2.3M PSTVPlus Therapeutics, Inc.4.80x -- $1.4M -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
50
AXTI alert for Mar 3
AXT, Inc. [AXTI] is down 13.21% over the past day.
Buy
53
AAOI alert for Mar 3
Applied Optoelectronics, Inc. [AAOI] is down 6.99% over the past day.
Sell
32
TPB alert for Mar 3
Turning Point Brands, Inc. [TPB] is up 0.13% over the past day.
